Glioblastoma - Category, Glioblastoma Multiforme
Conditions
Keywords
Border Zone Stereotactic Radiosurgery, Bevacizumab, Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Magnetic Resonance Spectroscopy, Glioblastoma, Brain Cancer, Brain Tumor, Radiosurgery
Brief summary
This is a phase II study on the usage of stereotactic Gamma Knife radiosurgery as a boost to the tumor bed border zone in conjunction with the usage of bevacizumab.
Detailed description
Glioblastoma Multiforme (GBM) is the most common primary brain tumor in adults. Unfortunately, despite aggressive surgery, radiation therapy (RT) and chemotherapy, the prognosis for this disease is poor. It is our hypothesis that GBM is a local disease wherein treatment failure is due to failure to eradicate tumor cells in the pathways along which the tumor eventually spreads (the border zone). The investigators hypothesize that treatment volume escalation will be successful at improving overall survival in patients with GBM when appropriate targeting and precision dose delivery is performed in a single treatment session. The 'border zone' of the tumor will be targeted for SRS (defined as a combination of the MRI volume of gadolinium enhancement plus up to 2 cm of the surrounding T2 volume). This represents the volume of tumor infiltrated white matter and is the route of GBM spread. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), has been used with safety and clinical success with concomitant chemotherapy in solid tumors, including GBM. The investigators further hypothesize that a combined approach of SRS with this VEGF inhibitor will be an effective strategy for GBM because bevacizumab will maximize the effects of radiation in the treated volume and potentially reduce radiation toxicity in the adjacent brain.
Interventions
DRUGBevacizumab
Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
Subjects will have MRS prior to BZ-SRS.
PROCEDUREBorder Zone Stereotactic Radiosurgery (BZ-SRS)
The 'border zone' of the tumor will be targeted by SRS in a single session.
Sponsors
Genentech, Inc.
Ajay Niranjan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed glioblastoma multiforme, WHO grade IV astrocytoma. 2. Prior first-line treatment with surgery or biopsy followed by fractionated radiotherapy with concurrent temozolomide-containing chemotherapy is required for glioblastoma patients. Additional prior chemotherapy is allowed, without limitation on number of recurrences. 3. An interval of at least 2 months since completion of fractionated radiotherapy. 4. Age \> 18 years 5. Life expectancy of at least 12 weeks. 6. Karnofsky Performance Status score (KPS) of ≥ 60 7. Documented recurrent disease; Disease must be evaluable, but does not need to be measurable; the target site for SRS does not need to be located in a previously-irradiated area. 8. All patients must have no restrictions to obtaining MRI with and without gadolinium contrast. 9. Adequate bone marrow, hepatic and renal function ; BUN \< 25 and Cr \< 1.7 10. Negative pregnancy test at the time of SRS in any patient who could be pregnant. 11. Willingness to forego additional therapy until evidence of disease progression
Exclusion criteria
1\. General Medical Exclusions: 1. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study. 2. Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last 3 years. 3. Prior radiosurgery 4. Prior intracavitary irradiation or Gliadel wafers. 2\. Disease-Specific Exclusions: 1. Inability to comply with protocol or study procedures 2. Prior treatment with bevacizumab. 3. Inability to undergo MRI with and without contrast administration. 3\. Bevacizumab-Specific Exclusions: 1. Inadequately controlled hypertension. 2. Prior history of hypertensive crisis or hypertensive encephalopathy. 3. New York Heart Association (NYHA) Grade II or greater congestive heart failure. 4. History of myocardial infarction or unstable angina within 6 months prior to Day 1. 5. History of stroke or transient ischemic attack within 6 months prior to Day 1. 6. Significant vascular disease within 6 months prior to Day 1. 7. History of hemoptysis within 1 month prior to Day 1. 8. Evidence of bleeding diathesis or significant coagulopathy 9. Major surgical procedure, open biopsy, or significant traumatic injury within 14 days prior to Day 1 or anticipation of need for major non -cranial surgical procedure during the course of the study. 10. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1. 11. History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1. 12. Serious, non-healing wound, active ulcer, or untreated bone fracture. 13. Proteinuria 14. Known hypersensitivity to any component of bevacizumab 15. Pregnancy (positive pregnancy test) or lactation. Use of effective means of contraception (men and women) in subjects of child-bearing potential.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 2 years | The number of months that a patient remains alive from the day first gamma knife surgery until the date of death or end of data collection for survival. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-month Progression-free Survival | At 6 months | The proportion of patients who did not experience disease progression per RANO as of 6 months from the date of radiosurgery. RANO (Response Assessment in Neuro-Oncology) Response Criteria for Progression using imaging features: 25% or more increase in enhancing lesions despite stable or increasing steroid dose increase (significant) in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes any new lesions clinical features clinical deterioration (not attributable to other non-tumor causes and not due to steroid decrease). Proportion of patients for PFS = number of patients without disease at 6 months post radiosurgery / total number of patients. |
| 6-month Overall Survival | At 6 months | The proportion of patients who remained alive as of 6 months from the date of radiosurgery. Proportion of patients for OS = number of patients alive at 6 months post radiosurgery / total number of patients. |
| CNS Toxicity | Six months after SRS | The number of patients experiencing a CNS toxicity type occurring within 3 months of gamma knife surgery, as measured by RTOG/EORTC Acute Radiation Morbidity Scoring and the NCI CTCAE v4.0 for late toxicity. |
| Potential Value of Magnetic Resonance Spectroscopy (MRS) | Prior to radiosurgery | Improvement of border zone target selection and detection of therapeutic response of the derived treatment volumes between MRI and MRI+MRS (Magnetic Resonance Spectroscopy). This is presented as the number of patients for whom the derived treatment was changed as a result of the utilization of MRS. |
| Karnofsky Performance Status | At baseline (Week 0) prior to treatment administration | The Karnofsky Performance Scale Index allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. Score range from 0 to 100; the lower the Karnofsky score, the worse the survival for most serious illnesses. A score of 100 would indicate 'Normal no complaints; no evidence of disease.' A score of 50 indicates 'Requires considerable assistance and frequent medical care.' A score of 0-10 would indicate 'Moribund; fatal processes progressing rapidly' and 'Death'. |
| Tumor Response | Up to 2 years | Proportion of patients with a best response of CR, PR, SD, PD: number of patients with CR, PR, SD or PD / total number of patients evaluable for response to treatment of border zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab. |
| Center for Epidemiological Studies Depression Scale (CES-D) | At baseline (Week 0) prior to treatment administration | An assessment comprised of 20 statements for which the participant is asked to indicate how often they have felt a certain way during the past week. SCORING: zero for answers of Rarely or none of the time (less than 1 day), 1 for answers of Some or a little of the time (1-2 days), 2 for answers of Occasionally or a moderate amount of time (3-4 days) the third column, 3 for answers of Most or all of the time (5-7 days). The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more depression symptomatology. |
| Functional Assessment of Cancer - General (FACT-G) | At baseline (Week 0) prior to treatment administration | The FACT-G is a patient rated, 27-item compilation of general questions divided into 4 primary Quality of Life (QOL) sub-scales: physical well-being (PWB; 7-items, score range 0-28), social/family well-being (SWB; 7-items, score range 0-28), emotional well-being (EWB; 6-items, score range 0-24), and functional well-being (FWB; 7-items, score range 0-28). This tool represents the generic core questionnaire that are utilized in combination with cancer site-specific questionnaires, (FBrain, in this study) Overall score and four subscale scores with ranges and distributions that are sample-specific can be calculated.FACT-G is scored by summing the individual scale scores; higher scores indicate better quality of life. FACT-G uses 5-point rating scale ranging from (0) = Not at all; (1) = A little bit; (2) = Somewhat; (3) = Quite a bit; to (4) = Very much.The FACT-G total score is the sum of the four subscale scores (if least 80% completed) and has a possible range of 0-108 points. |
| Functional Assessment of Cancer Therapy-General - General (FACT-G) | At 8 weeks | The FACT-G is a patient rated, 27-item compilation of general questions divided into 4 primary Quality of Life (QOL) sub-scales: physical well-being (PWB; 7-items, score range 0-28), social/family well-being (SWB; 7-items, score range 0-28), emotional well-being (EWB; 6-items, score range 0-24), and functional well-being (FWB; 7-items, score range 0-28). This tool represents the generic core questionnaire that are utilized in combination with cancer site-specific questionnaires, (FBrain, in this study) Overall score and four subscale scores with ranges and distributions that are sample-specific can be calculated.FACT-G is scored by summing the individual scale scores; higher scores indicate better quality of life. FACT-G uses 5-point rating scale ranging from (0) = Not at all; (1) = A little bit; (2) = Somewhat; (3) = Quite a bit; to (4) = Very much.The FACT-G total score is the sum of the four subscale scores (if least 80% completed) and has a possible range of 0-108 points. |
| Functional Assessment of Cancer Therapy-Brain Specific Symptom Index (FACT-BrSI) | At baseline (Week 0) prior to treatment administration | The FACT-BrSI subscale, brain tumor specific version (2007), is a 15-item, patient completed, questionnaire.This brain subscale is used along with the core (general) questionnaire (FACT-G) that includes 27 items. Patients rate all items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher quality of life (QOL). The FACT BrSI has a range of 0-60, where a higher score indicates less symptomatology. |
| Barthel's Index of Activities of Daily Living Assessment | At baseline (Week 0) prior to treatment administration | The Barthel Index consists items assessing the ability to achieve certain activities without assistance. It evaluates the ability of feeding, moving from wheelchair to bed and returning, doing personal toilet, getting on and off toilet,bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. Scoring ranged from 0 (completely dependent) to 20 (completely independent) for this assessment. A maximal score of 20 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| BZ-SRS With Bevacizumab All patients received Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally received bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until disease progression. One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS. Patients will have MRS Magnetic Resonance Spectroscopy (MRS)prior to BZ-SRS. Border Zone Stereotactic Radiosurgery (BZ-SRS): The 'border zone' of the tumor will be targeted by SRS in a single session. | 16 |
| Total | 16 |
Baseline characteristics
| Characteristic | BZ-SRS With Bevacizumab |
|---|---|
| Age, Continuous | 62 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 16 Participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 14 / 16 |
| other Total, other adverse events | 15 / 16 |
| serious Total, serious adverse events | 7 / 16 |
Outcome results
Primary
Overall Survival (OS)
The number of months that a patient remains alive from the day first gamma knife surgery until the date of death or end of data collection for survival.
Time frame: Up to 2 years
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Overall Survival (OS) | 11.73 months |
Secondary
6-month Overall Survival
The proportion of patients who remained alive as of 6 months from the date of radiosurgery. Proportion of patients for OS = number of patients alive at 6 months post radiosurgery / total number of patients.
Time frame: At 6 months
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | 6-month Overall Survival | Death within 6 months of treatment | 0.0625 proportion of participants |
| BZ-SRS With Bevacizumab | 6-month Overall Survival | Alive after 6 months of treatment | 0.938 proportion of participants |
Secondary
6-month Progression-free Survival
The proportion of patients who did not experience disease progression per RANO as of 6 months from the date of radiosurgery. RANO (Response Assessment in Neuro-Oncology) Response Criteria for Progression using imaging features: 25% or more increase in enhancing lesions despite stable or increasing steroid dose increase (significant) in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumor causes any new lesions clinical features clinical deterioration (not attributable to other non-tumor causes and not due to steroid decrease). Proportion of patients for PFS = number of patients without disease at 6 months post radiosurgery / total number of patients.
Time frame: At 6 months
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | 6-month Progression-free Survival | Death or disease progression ≤ 6mons of treatment | 0.438 proportion of participants |
| BZ-SRS With Bevacizumab | 6-month Progression-free Survival | Alive or stable disease ≥ 6 months of treatment | 0.562 proportion of participants |
Secondary
Barthel's Index of Activities of Daily Living Assessment
The Barthel Index consists items assessing the ability to achieve certain activities without assistance. It evaluates the ability of feeding, moving from wheelchair to bed and returning, doing personal toilet, getting on and off toilet,bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. Scoring ranged from 0 (completely dependent) to 20 (completely independent) for this assessment. A maximal score of 20 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state.
Time frame: At baseline (Week 0) prior to treatment administration
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Barthel's Index of Activities of Daily Living Assessment | 17.77 score on a scale |
Secondary
Barthel's Index of Activities of Daily Living Assessment
The Barthel Index consists items assessing the ability to achieve certain activities without assistance. It evaluates the ability of feeding, moving from wheelchair to bed and returning, doing personal toilet, getting on and off toilet,bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. Scoring ranged from 0 (completely dependent) to 20 (completely independent) for this assessment. A maximal score of 20 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state.
Time frame: At 8 weeks
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Barthel's Index of Activities of Daily Living Assessment | 16.30 score on a scale |
Secondary
Center for Epidemiological Studies Depression Scale (CES-D)
An assessment comprised of 20 statements for which the participant is asked to indicate how often they have felt a certain way during the past week. SCORING: zero for answers of Rarely or none of the time (less than 1 day), 1 for answers of Some or a little of the time (1-2 days), 2 for answers of Occasionally or a moderate amount of time (3-4 days) the third column, 3 for answers of Most or all of the time (5-7 days). The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more depression symptomatology.
Time frame: At baseline (Week 0) prior to treatment administration
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Center for Epidemiological Studies Depression Scale (CES-D) | 17.0 score on a scale |
Secondary
Center for Epidemiological Studies Depression Scale (CES-D)
An assessment comprised of 20 statements for which the participant is asked to indicate how often they have felt a certain way during the past week. SCORING: zero for answers of Rarely or none of the time (less than 1 day), 1 for answers of Some or a little of the time (1-2 days), 2 for answers of Occasionally or a moderate amount of time (3-4 days) the third column, 3 for answers of Most or all of the time (5-7 days). The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more depression symptomatology.
Time frame: At 8 weeks
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Center for Epidemiological Studies Depression Scale (CES-D) | 20.2 score on a scale |
Secondary
CNS Toxicity
The number of patients experiencing a CNS toxicity type occurring within 3 months of gamma knife surgery, as measured by RTOG/EORTC Acute Radiation Morbidity Scoring and the NCI CTCAE v4.0 for late toxicity.
Time frame: Six months after SRS
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | CNS Toxicity | Muscle Weakness Lower Limb | 1 number of participants |
| BZ-SRS With Bevacizumab | CNS Toxicity | Fatigue and Dehydration | 1 number of participants |
| BZ-SRS With Bevacizumab | CNS Toxicity | Spinal Fracture and Pain | 1 number of participants |
Secondary
Functional Assessment of Cancer - General (FACT-G)
The FACT-G is a patient rated, 27-item compilation of general questions divided into 4 primary Quality of Life (QOL) sub-scales: physical well-being (PWB; 7-items, score range 0-28), social/family well-being (SWB; 7-items, score range 0-28), emotional well-being (EWB; 6-items, score range 0-24), and functional well-being (FWB; 7-items, score range 0-28). This tool represents the generic core questionnaire that are utilized in combination with cancer site-specific questionnaires, (FBrain, in this study) Overall score and four subscale scores with ranges and distributions that are sample-specific can be calculated.FACT-G is scored by summing the individual scale scores; higher scores indicate better quality of life. FACT-G uses 5-point rating scale ranging from (0) = Not at all; (1) = A little bit; (2) = Somewhat; (3) = Quite a bit; to (4) = Very much.The FACT-G total score is the sum of the four subscale scores (if least 80% completed) and has a possible range of 0-108 points.
Time frame: At baseline (Week 0) prior to treatment administration
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg). (NOTE: One participant did not complete the EWB section of the questionnaire. One participant did not complete the FWB section of the questionnaire.)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer - General (FACT-G) | Physical Well-Being | 18.9 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer - General (FACT-G) | Emotional Well-Being | 15.8 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer - General (FACT-G) | Functional Well-Being | 16.8 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer - General (FACT-G) | Total Well-Being | 75.8 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer - General (FACT-G) | Social Well-Being | 23.6 score on a scale |
Secondary
Functional Assessment of Cancer Therapy-Brain Specific Symptom Index (FACT-BrSI)
The FACT-BrSI subscale, brain tumor specific version (2007), is a 15-item, patient completed, questionnaire.This brain subscale is used along with the core (general) questionnaire (FACT-G) that includes 27 items. Patients rate all items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher quality of life (QOL). The FACT BrSI has a range of 0-60, where a higher score indicates less symptomatology.
Time frame: At baseline (Week 0) prior to treatment administration
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-Brain Specific Symptom Index (FACT-BrSI) | 39.7 score on a scale |
Secondary
Functional Assessment of Cancer Therapy-Brain Specific Symptom Index (FACT-BrSI)
The FACT-BrSI subscale, brain tumor specific version (2007), is a 15-item, patient completed, questionnaire.This brain subscale is used along with the core (general) questionnaire (FACT-G) that includes 27 items. Patients rate all items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher quality of life (QOL). The FACT BrSI has a range of 0-60, where a higher score indicates less symptomatology.
Time frame: At 8 weeks
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-Brain Specific Symptom Index (FACT-BrSI) | 40.5 score on a scale |
Secondary
Functional Assessment of Cancer Therapy-General - General (FACT-G)
The FACT-G is a patient rated, 27-item compilation of general questions divided into 4 primary Quality of Life (QOL) sub-scales: physical well-being (PWB; 7-items, score range 0-28), social/family well-being (SWB; 7-items, score range 0-28), emotional well-being (EWB; 6-items, score range 0-24), and functional well-being (FWB; 7-items, score range 0-28). This tool represents the generic core questionnaire that are utilized in combination with cancer site-specific questionnaires, (FBrain, in this study) Overall score and four subscale scores with ranges and distributions that are sample-specific can be calculated.FACT-G is scored by summing the individual scale scores; higher scores indicate better quality of life. FACT-G uses 5-point rating scale ranging from (0) = Not at all; (1) = A little bit; (2) = Somewhat; (3) = Quite a bit; to (4) = Very much.The FACT-G total score is the sum of the four subscale scores (if least 80% completed) and has a possible range of 0-108 points.
Time frame: At 8 weeks
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-General - General (FACT-G) | Physical Well-Being | 20.0 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-General - General (FACT-G) | Social Well-Being | 23.1 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-General - General (FACT-G) | Emotional Well-Being | 16.4 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-General - General (FACT-G) | Functional Well-Being | 15.8 score on a scale |
| BZ-SRS With Bevacizumab | Functional Assessment of Cancer Therapy-General - General (FACT-G) | Total Well-Being | 75.3 score on a scale |
Secondary
Karnofsky Performance Status
The Karnofsky Performance Scale Index allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. Score range from 0 to 100; the lower the Karnofsky score, the worse the survival for most serious illnesses. A score of 100 would indicate 'Normal no complaints; no evidence of disease.' A score of 50 indicates 'Requires considerable assistance and frequent medical care.' A score of 0-10 would indicate 'Moribund; fatal processes progressing rapidly' and 'Death'.
Time frame: At baseline (Week 0) prior to treatment administration
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | Karnofsky Performance Status | Karnofsky Performance Status Score: 40 | 0 participants |
| BZ-SRS With Bevacizumab | Karnofsky Performance Status | Karnofsky Performance Status Score: 60 | 0 participants |
| BZ-SRS With Bevacizumab | Karnofsky Performance Status | Karnofsky Performance Status Score: 70 | 4 participants |
| BZ-SRS With Bevacizumab | Karnofsky Performance Status | Karnofsky Performance Status Score: 80 | 6 participants |
| BZ-SRS With Bevacizumab | Karnofsky Performance Status | Karnofsky Performance Status Score: 90 | 6 participants |
| BZ-SRS With Bevacizumab | Karnofsky Performance Status | Karnofsky Performance Status Score: 100 | 0 participants |
Secondary
Potential Value of Magnetic Resonance Spectroscopy (MRS)
Improvement of border zone target selection and detection of therapeutic response of the derived treatment volumes between MRI and MRI+MRS (Magnetic Resonance Spectroscopy). This is presented as the number of patients for whom the derived treatment was changed as a result of the utilization of MRS.
Time frame: Prior to radiosurgery
Population: Participants who received MRS (Magnetic Resonance Spectroscopy) scans prior to radiosurgery.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| BZ-SRS With Bevacizumab | Potential Value of Magnetic Resonance Spectroscopy (MRS) | 0 number of participants |
Secondary
Tumor Response
Proportion of patients with a best response of CR, PR, SD, PD: number of patients with CR, PR, SD or PD / total number of patients evaluable for response to treatment of border zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab.
Time frame: Up to 2 years
Population: Patients with recurrent or Progressive Glioblastoma Multiforme who underwent treatment of border Zone Stereotactic Radiosurgery (BZ-SRS) with bevacizumab (10 mg/kg).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| BZ-SRS With Bevacizumab | Tumor Response | Progressed Disease | 0.077 Proportion of participants |
| BZ-SRS With Bevacizumab | Tumor Response | Complete Response | 0.077 Proportion of participants |
| BZ-SRS With Bevacizumab | Tumor Response | Partial Response | 0.308 Proportion of participants |
| BZ-SRS With Bevacizumab | Tumor Response | Stable Disease | 0.538 Proportion of participants |